Novavax Inc. Stock
€13.87
Your prediction
Novavax Inc. Stock
Pros and Cons of Novavax Inc. in the next few years
Pros
Cons
Performance of Novavax Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novavax Inc. | -0.400% | -2.926% | 241.359% | 84.241% | 210.549% | -88.520% | 181.144% |
| Ardelyx Inc. | 3.070% | 1.608% | 5.441% | 102.500% | 9.308% | 7.085% | - |
| Evolus Inc | - | 0.000% | 7.477% | 37.725% | 27.072% | 32.948% | - |
| Salarius Pharmaceuticals Inc. | - | -3.015% | -6.311% | -66.724% | -30.450% | -98.501% | -99.994% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.General Impression
The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.
Detailed Analysis
Comments
News
Better Buy: Inovio Pharmaceuticals vs. Novavax
The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to dominate this market were much less successful
3 Things You Need to Know If You Buy Novavax Today
Novavax (NASDAQ: NVAX) stock has both soared and plummeted at times in recent years. Investors initially bet on the biotech company to be a winner in the coronavirus vaccine race, sending the stock
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Vaccine maker Novavax (NASDAQ: NVAX) isn't dead in the water after all. Though the past 18 months have been tough -- and management warned investors that the business might sink soon -- Novavax